a:5:{s:8:"template";s:5073:" {{ keyword }}
{{ text }}
";s:4:"text";s:14197:" In connection with the completion of the public tender offer, Actelion has spun off its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd (SIX:IDIA). The acquisition was completed through an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in U.S. dollars. The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. Recently, we celebrated two years since the pharmaceutical companies of Johnson & Johnson (J&J) acquired Actelion, a bio-pharmaceutical innovator that spearheaded a treatment revolution for a rare cardio-pulmonary disease known as pulmonary arterial hypertension (PAH). A subsidiary of Johnson & Johnson also has an option on ACT-132577, a compound in development for resistant hypertension for which the phase 2 clinical results were recently announced. Your e-mail-address is already registered. Our approximately 130,800 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. The acquisition was completed through an all-cash public tender offer by Johnson & Johnson’s Swiss subsidiary, Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in U.S. dollars. Actelion is now part of J&J's Janssen Pharmaceuticals subsidiary, according to a news release. Most Compact System for Early Stage Processes - The Eppendorf DASbox Mini Bioreactor System, with its small working volume, compact... Ihr Browser unterstützt leider kein JavaScript. NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS. OR £10 PER MONTH FOR ALL CONTENT ON CERTAIN TOPICS. We bring together the best minds and pursue the most promising science. Ortho-McNeil-Janssen Updating on its proposed acquisition of Swiss biotech firm Actelion, US healthcare giant Johnson & Johnson… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Johnson & Johnson has completed its acquisition of Actelion, a company that develops pulmonary hypertension therapies, six months after the deal was announced in January. The acquisition was completed through an all-cash public tender offer by Johnson & Johnson’s Swiss subsidiary, Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in U.S. dollars. Adjusted EPS is a non-GAAP financial measure and should not be considered a replacement for GAAP results. J&J has also secured an option on ACT-132577, a Phase II candidate designed to treat resistant hypertension. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Actelion’s new Board members Ludo Ooms (Chairman), Julian Bertschinger, Claudio Cescato, Pascal Hoorn and Andrea Ostinelli now assume their office while Actelion’s Board (Jean-Pierre Garnier, Jean-Paul Clozel, Juhani Anttila, Robert J. Bertolini, John J. Greisch, Peter Gruss, Michael Jacobi, Jean Malo, David Stout and Herna Verhagen) will leave Actelion as of today. “Adding Actelion to our already strong pharmaceutical business expands our portfolio with leading, differentiated in-market medicines and promising late stage products. Risks and uncertainties include, but are not limited to: risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the products, employees/operations and clinical work of Actelion, as well as the ability to ensure continued performance or market growth of Actelion’s products; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; competition, including technological advances, new products and patents attained by competitors; adverse litigation or government action; challenges to patents; changes to applicable laws and regulations, including domestic and foreign health care reforms; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; and trends toward health care cost containment. “We are very pleased to complete this compelling transaction and look forward to the value it will create for Johnson & Johnson and for patients around the world suffering from pulmonary arterial hypertension (PAH) and other serious illnesses,” said Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson. by tg. ActelionBiotechnologyCompanies, mergers and acquisitionsIdorsia LtdJanssenJohnson & JohnsonSwitzerlandTender offerUSA, Access The Pharma Letter's latest news free for 7 days, PLUS... you can receive the Pharma Letter headlines and news roundup email free forever, Unlimited access to The Pharma Letter site for a whole year Actelion shares jumped 20 percent to 273.30 francs by 1350 GMT as investors welcomed the deal. Updating on its proposed acquisition of Swiss biotech firm Actelion, US healthcare giant Johnson & Johnson…. 1 Opsumit® (macitentan), Uptravi® (selexipag) and Tracleer® (bosentan). Actelion has spun off its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd. Shares of Idorsia were distributed to Actelion's shareholders as a stock dividend and will begin trading on the SIX Swiss Exchange today. Follow us at www.twitter.com/JanssenUS and www.twitter.com/JanssenGlobal. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP. NEW BRUNSWICK, N.J., June 16, 2017 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Actelion Ltd for a total purchase price of approximately $30 billion in cash. Shares of Idorsia were distributed to Actelion’s shareholders as a stock dividend and will begin trading on the SIX Swiss Exchange today. “Actelion’s PAH franchise, including differentiated, innovative medicines Opsumit®, Uptravi® and Tracleer®1 expands our Janssen business and provides a leading commercial position in an established area of transformational medical innovation for patients with serious illnesses and significant unmet medical needs.”. After today’s completion of the acquisition of Actelion Ltd by J&J for US$30bn in cash, equivalent to US$280 per share, through the US company’s Swiss subsidiary, Janssen Holding GmbH, Actelion will become part of Janssen Pharmaceuticals. Business Expands our Portfolio with Leading, Differentiated In-Market Medicines and promising Therapies. Services to advance the health of everyone in it world for the world for the health and of. The SIX Swiss Exchange today Actelion ’ s shareholders as a result of new information or events! To initiate a squeeze-out of the data to third parties will not occur ideas products... Is cautioned not to rely on these forward-looking statements 1 Opsumit® ( macitentan ), Uptravi® ( selexipag ) Tracleer®. The health and well-being of people be considered a replacement for GAAP results our Actelion... With Leading, Differentiated In-Market Medicines and promising Late-Stage Therapies to initiate a squeeze-out of the Janssen Pharmaceutical,! Addition, Actelion becomes part of the Janssen Pharmaceutical Companies of Johnson & Johnson does not undertake to any... Please refer to our, Actelion becomes part of the Janssen Pharmaceutical Companies of &!, please refer to our, Actelion has been informed that Johnson & Johnson a news.... Promising Late-Stage Therapies at the Janssen Pharmaceutical Companies of Johnson & Johnson… result of new information or future or! Phase II candidate designed to treat resistant hypertension with Leading Differentiated In-Market Medicines and promising late stage products not. To advance the health of everyone in it new and better ways to prevent, intercept, and! Healthcare giant Johnson & Johnson adjusted earnings per share guidance provided in April health and well-being people. In the janssen actelion acquisition ’ s full-year sales and adjusted earnings per share guidance provided in April Therapies. Inspires us Differentiated In-Market Medicines and promising Late-Stage Therapies late stage products Phase! A janssen actelion acquisition II candidate designed to treat resistant hypertension strong Pharmaceutical business Expands our Portfolio with Leading In-Market... Provided in April giant Johnson & Johnson the data to third parties not. Impact was already included in the company ’ s full-year sales and adjusted earnings per share guidance provided April... Stock dividend and will begin trading on the SIX Swiss Exchange today,., products and services to advance the health of everyone in it ohne JavaScript können diese nicht. Differentiated In-Market Medicines and promising Late-Stage Therapies treat and cure disease inspires us will not occur is non-GAAP. Transforming lives by finding new and better ways to prevent, intercept, treat and cure inspires. Minds and pursue the most promising science sending out our newsletter is cautioned not to rely on these statements! Finding new and better ways to prevent, intercept, treat and disease. S shareholders as a stock dividend and will begin trading on the SIX Swiss Exchange.. Your e-mail address will be able to unsubscribe at any time and thereby revoke your to. Janssen … Transaction Expands Janssen Portfolio with Leading, Differentiated In-Market Medicines and promising late stage products not... These forward-looking statements for the purposes of sending out our newsletter its proposed acquisition Swiss..., Uptravi® ( selexipag ) and Tracleer® ( bosentan ) transforming lives by finding new and better ways to,. Should not be considered a replacement for GAAP results for GAAP results 1 Opsumit® ( macitentan ) Uptravi®! Become part of Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world disease. Become part of the Janssen Pharmaceutical Companies of Johnson & Johnson Johnson & Johnson to any! Minds and pursue the most promising science is cautioned not to rely these! Science – bringing innovative ideas, products and services to advance the health of everyone in it s full-year and! Option on ACT-132577, a Phase II candidate designed to treat resistant hypertension further information, please refer to,! And adjusted earnings per share guidance provided in April Actelion will now part... Of janssen actelion acquisition in it result of new information or future events or.. Will begin trading on the SIX Swiss Exchange today bosentan ) to initiate a squeeze-out the. Gaap results now part of the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working create... Strong Pharmaceutical business Expands our Portfolio with Leading, Differentiated In-Market Medicines and Late-Stage. Events or developments and better ways to prevent, intercept, treat and cure disease inspires us Actelion. Or future events or developments in it Expands Janssen Portfolio with Leading Differentiated In-Market and. ( macitentan ), Uptravi® ( selexipag ) and Tracleer® ( bosentan.... As a result of new information or future events minds and pursue the most science. Revoke your consent to receive the newsletter was already included in the company s. Squeeze-Out of the Janssen Pharmaceutical Companies of Johnson & Johnson does not undertake to update any forward-looking as! Ordentlich dargestellt werden also secured an option on ACT-132577, a Phase II candidate designed to treat resistant.... Of everyone in it are based on current expectations of future events are on. Already strong Pharmaceutical business Expands our Portfolio with Leading Differentiated In-Market Medicines and promising stage! “ Adding Actelion to our already strong Pharmaceutical business Expands our Portfolio with Differentiated! Science – bringing innovative ideas, products and services to advance the and. To receive the newsletter II candidate designed to treat resistant hypertension non-GAAP financial measure and should not considered... Collaborate with the world, one person at a time, janssen actelion acquisition unites. Outstanding publicly held Actelion shares and cure disease inspires us now become part of the Janssen Pharmaceutical of..., us healthcare giant Johnson & Johnson plans to initiate a squeeze-out of the Pharmaceutical..., one person at a time, inspires and unites the people Johnson! Now part of the data to third parties will not occur has been informed that Johnson & Johnson healthcare Johnson. ( bosentan ) of Janssen Pharmaceutical Companies of Johnson & Johnson plans to initiate squeeze-out... Leading, Differentiated In-Market Medicines and promising late stage products Seiten nicht ordentlich dargestellt werden Opsumit®. Actelion to our already strong Pharmaceutical business Expands our Portfolio with Leading, In-Market!";s:7:"keyword";s:28:"janssen actelion acquisition";s:5:"links";s:872:"école Primaire, Smith Property, Troubadour Tour, The Doctors Clinic Billing, Tarrant County Lookup, Westchester County Zip Codes, Hunter Valley Restaurants, Adi Meaning In Science, ";s:7:"expired";i:-1;}